Physician profile
Avinash Chandra
NPI 1013190651
$7,970.94
in general payments reported to CMS, 2019-2025
14 companies · $6,278 in 2025
The $6,278 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $13.92 · 2022: $26.38 · 2023: $1,254 · 2024: $126 · 2025: $6,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,376 · Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,376.10 |
| Food and Beverage | $2,280.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,395.15 | 2023-2025 | Triclip, Mitraclip |
| Edwards Lifesciences Corporation | $3,044.99 | 2025 | Evoque, Pascal |
| Novartis Pharmaceuticals Corporation | $201.62 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $75.22 | 2019-2022 | |
| Abiomed | $46.27 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $39.27 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $36.58 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.47 | 2019-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $20.33 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $19.16 | 2019 | |
| Amgen INC. | $16.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.79 | 2025 | Evkeeza |
| Amarin Pharma, INC. | $15.07 | 2019 | |
| Pfizer INC. | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.